![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CELF4 |
Gene summary for CELF4 |
![]() |
Gene information | Species | Human | Gene symbol | CELF4 | Gene ID | 56853 |
Gene name | CUGBP Elav-like family member 4 | |
Gene Alias | BRUNOL4 | |
Cytomap | 18q12.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9BZC1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56853 | CELF4 | HTA12-15-2 | Human | Pancreas | PDAC | 2.25e-02 | 3.57e-01 | 0.2315 |
56853 | CELF4 | HTA12-23-1 | Human | Pancreas | PDAC | 6.77e-03 | 5.48e-01 | 0.3405 |
56853 | CELF4 | HTA12-25-1 | Human | Pancreas | PDAC | 2.43e-03 | 4.69e-01 | 0.313 |
56853 | CELF4 | HTA12-26-1 | Human | Pancreas | PDAC | 3.93e-15 | 8.25e-01 | 0.3728 |
56853 | CELF4 | HTA12-29-1 | Human | Pancreas | PDAC | 5.15e-35 | 7.73e-01 | 0.3722 |
56853 | CELF4 | male-WTA | Human | Thyroid | PTC | 2.29e-02 | 1.10e-01 | 0.1037 |
56853 | CELF4 | PTC01 | Human | Thyroid | PTC | 5.96e-08 | 2.03e-01 | 0.1899 |
56853 | CELF4 | PTC03 | Human | Thyroid | PTC | 9.48e-05 | 1.82e-01 | 0.1784 |
56853 | CELF4 | PTC05 | Human | Thyroid | PTC | 1.21e-08 | 5.37e-01 | 0.2065 |
56853 | CELF4 | PTC06 | Human | Thyroid | PTC | 2.22e-22 | 6.46e-01 | 0.2057 |
56853 | CELF4 | PTC07 | Human | Thyroid | PTC | 2.80e-17 | 3.61e-01 | 0.2044 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005068516 | Thyroid | PTC | positive regulation of mRNA processing | 24/5968 | 32/18723 | 6.76e-07 | 1.07e-05 | 24 |
GO:0000381111 | Thyroid | PTC | regulation of alternative mRNA splicing, via spliceosome | 37/5968 | 60/18723 | 1.93e-06 | 2.64e-05 | 37 |
GO:003424916 | Thyroid | PTC | negative regulation of cellular amide metabolic process | 122/5968 | 273/18723 | 5.50e-06 | 6.64e-05 | 122 |
GO:001714815 | Thyroid | PTC | negative regulation of translation | 108/5968 | 245/18723 | 3.75e-05 | 3.48e-04 | 108 |
GO:0048026110 | Thyroid | PTC | positive regulation of mRNA splicing, via spliceosome | 16/5968 | 22/18723 | 9.98e-05 | 8.15e-04 | 16 |
GO:00002459 | Thyroid | PTC | spliceosomal complex assembly | 39/5968 | 79/18723 | 8.86e-04 | 5.40e-03 | 39 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CELF4 | ISLET | Pancreas | ADJ | KIAA1324,PTPRN2,CACNA1A, etc. | 3.46e-01 | ![]() |
CELF4 | ISLET | Pancreas | PDAC | KIAA1324,PTPRN2,CACNA1A, etc. | 1.98e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CELF4 | SNV | Missense_Mutation | c.270C>A | p.Phe90Leu | p.F90L | Q9BZC1 | protein_coding | tolerated(0.25) | benign(0.034) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CELF4 | SNV | Missense_Mutation | c.707N>A | p.Arg236His | p.R236H | Q9BZC1 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CELF4 | SNV | Missense_Mutation | novel | c.1333N>T | p.Gly445Cys | p.G445C | Q9BZC1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CELF4 | SNV | Missense_Mutation | c.554G>A | p.Arg185His | p.R185H | Q9BZC1 | protein_coding | deleterious(0) | possibly_damaging(0.745) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
CELF4 | SNV | Missense_Mutation | novel | c.144G>A | p.Met48Ile | p.M48I | Q9BZC1 | protein_coding | deleterious(0.03) | benign(0.354) | TCGA-ZJ-AAXN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CELF4 | SNV | Missense_Mutation | c.706C>T | p.Arg236Cys | p.R236C | Q9BZC1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CELF4 | SNV | Missense_Mutation | c.1085N>C | p.Ile362Thr | p.I362T | Q9BZC1 | protein_coding | deleterious(0.01) | benign(0.299) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CELF4 | SNV | Missense_Mutation | c.707N>A | p.Arg236His | p.R236H | Q9BZC1 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CELF4 | SNV | Missense_Mutation | c.622N>A | p.Ala208Thr | p.A208T | Q9BZC1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
CELF4 | SNV | Missense_Mutation | rs372830155 | c.923N>T | p.Ala308Val | p.A308V | Q9BZC1 | protein_coding | tolerated(0.73) | benign(0.001) | TCGA-AZ-5407-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
56853 | CELF4 | NA | iloperidone | ILOPERIDONE | 18521091 |
Page: 1 |